By ushering this new era of precision medicine, President Obama in effect recognized the many years of groundbreaking research dedicated to the identification of the genetic causes of diseases. While the short-term goals of the PMI centered on development of new therapies in oncology, the long-term goals extend to all areas in health and healthcare. The application of precision medicine in other complex disease processes, such as cardiovascular disease, have gained burgeoning momentum with increased financial support and a widely-accepted scientific rationale.
At Medpace, we recognize the importance of the emerging role of precision medicine in the field of cardiovascular disease. To optimize support in the design and execution of cardiovascular clinical trials that employ a precision medicine strategy, we have initiated a Cardiovascular Precision Medicine Program (CVPMP). As an extension of the Cardiovascular Division, the CVPMP is comprised of cardiovascular experts with extensive knowledge in the field of precision medicine, who aim to create a highly specialized partnership with industry sponsors seeking to develop therapies focused on disease subphenotypes and employ a patient-tailored approach. Medpace continues to lead the CRO industry in the early recognition of major clinical currents to generate nimble responses for the development of safe and effective medical therapies.
The goal of precision medicine is to move away from population averages and medians and instead, focus on the subject’s individual unique phenotype, as well as response to treatment
“Precision medicine leads to precision trials, by targeting subgroups that are more likely to display drug effect, i.e., smaller but ‘smarter’ over larger and ‘dumber’ trials,” commented Richard Lee, MD Senior Medical Director, Medical Department, Cardiovascular Precision Medicine. “The goal of precision medicine is to move away from population averages and medians and instead, focus on the subject’s individual unique phenotype, as well as response to treatment. With Medpace’s newly launched program, we are excited to work with Sponsors who are on the forefront of working on medical therapies that are based on precision medicine principles,” concluded Dr. Lee.
New Whitepaper – The Promise of Precision Medicine for Cardiovascular Disease & The Potential Impact on Clinical Trials
Dr. Lee recently authored a new whitepaper that addresses the promise of precision medicine for cardiovascular disease and the potential impact on clinical trials. The whitepaper discusses the role of precision medicine in the diagnosis, prevention, and treatment of cardiovascular disease and comments on the potential of precision medicine strategies in cardiovascular clinical trials. Topics include:
- What is Precision Medicine?
- How has the definition evolved over the years and what is the goal?
- The Role of Precision Medicine in Cardiovascular Disease and Cardiovascular Clinical Trials
- Tools and Applications Used in Precision Medicine
- A look at the non-traditional tools and applications that characterize a person’s disease phenotype for disease treatment and prevention
- Challenges and Barriers to Precision Medicine
You can read the Whitepaper: The Promise of Precision Medicine for Cardiovascular Disease & The Potential Impact on Clinical Trials in its entirety. To learn more about how Medpace can support your clinical development initiatives in this area, drop us a note.